Pfizer is voluntarily withdrawing its sickle cell disease (SCD) therapy Oxbryta from all world markets after finding an "imbalance" in deaths in its clinical trials programme. It's a blow to the ...

Pfizer's reported interest in acquiring sickle cell disease specialist Global Blood Therapeutics (GBT) has been confirmed, with the $68.50-per-share deal valuing GBT at $5.4 billion.

Sickle Cell Disease Market Insight, Epidemiology And Market Forecast - 2034The sickle cell disease treatment market is experiencing signific ...

PFE Pfizer Inc. 24.19 -0.21% Mkt cap 137.529B IndustryDrug Manufacturers—General MRK Merck & Co., Inc. 79.10 +0.34% Mkt cap 198.622B IndustryDrug Manufacturers—General JNJ Johnson & Johnson 152.41 ...

PFE Pfizer Inc. 25.04 +3.30% Mkt Cap 142.362B IndustryDrug Manufacturers—General MRK Merck & Co., Inc. 81.81 +3.35% Mkt Cap 205.427B IndustryDrug Manufacturers—General JNJ Johnson & Johnson 155.92 ...